24/7 Market News Snapshot 16 December, 2024 – Genprex, Inc. Common Stock (NASDAQ:GNPX)

December 16, 2024

DENVER, Colo., 16 December, 2024 (247marketnews.com) – (NASDAQ:GNPX) are discussed in this article.
Genprex, Inc. has recently experienced fluctuations in its stock performance, opening at $1.182 but currently trading at $1.086, reflecting a decrease of approximately 6.38%. After closing the previous session at $1.160, today’s trading volume reached 2.38 million shares, showcasing significant investor engagement. This price action suggests a bearish sentiment, compelling traders to monitor key support levels, particularly around $1.05, as they look for signs of recovery or potential consolidations in upcoming sessions.

Significantly, the company has made strides in its clinical research endeavors, completing the Phase 1 dose escalation segment of the Acclaim-3 clinical trial. This trial investigates Reqorsa® Gene Therapy in combination with Tecentriq® for the treatment of extensive stage small cell lung cancer (ES-SCLC). The results have established a favorable safety profile for this combination therapy, as confirmed by the Safety Review Committee (SRC), which has granted approval to move forward to the Phase 2 expansion of the trial.

The combination therapy has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) and an Orphan Drug Designation for Reqorsa, highlighting its potential to provide significant treatment alternatives for patients with this aggressive form of cancer. The SRC has identified a Recommended Phase 2 Dose (RP2D) of 0.12 mg/kg, marking the highest dose level tested without any dose-limiting toxicities reported.

Ryan Confer, President and Chief Executive Officer of Genprex, expressed enthusiasm regarding the progress made in the trial and emphasized the importance of partnerships with community-based oncology practices in facilitating rapid patient enrollment. The early trial data is promising, indicating that some patients experienced at least a 30% reduction in tumor size with the treatment. The Phase 2 segment aims to enroll around 50 patients, evaluating the 18-week progression-free survival rate, thus further exploring the clinical benefits of this innovative therapy. Genprex is committed to reshaping treatment options for cancer patients, looking forward to presenting findings from the Phase 1 portion at a clinical meeting in 2025.

Related news for (GNPX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.